Fig. 3.

Antibody responses aftervaccination usingPfSPZVaccine. To identify vaccination-induced antibodies, microarray reactivity in samples collected after the completed immunisation phase were compared to their individual baseline reactivity. (a, c) Median changes in IgG (a) and IgM (c) signal intensities across 262 microarray antigens over the immunisation phase were assessed amongst placebo recipients (n = 6), HIV negative (n = 5) and HIV positive vaccinees (n = 6). Antigens are sorted by median intensity changes in the HIV negative vaccinees´ group. (b, d) Volcano plots of fold change in IgG (b) and IgM (d) and p-values (paired Student's t-test) of average signal intensity in all vaccinees (n = 11) compared to their baseline for all microarray antigens. In addition, antibodies correlating with sterile protection (protected group: n = 4; unprotected group: n = 12) against CHMI were analysed for both IgG (e) and IgM (f). Differentially recognized antigens (p-value <0.05 and fold change >2) are depicted in red (see Table S1 for antigen abbreviations and Table S3–S8 for summary of data).